HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane Recruiting Phase 3 Trials for Capecitabine (DB01101)

IndicationStatusPhase
DBCOND0149684 (HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane)Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05424835A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and TaxaneTreatment